Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for...
Hence then, the article about wuxi biologics congratulates partner canbridge pharmaceuticals on the approval of innovative velaglucerase beta for injection gaurunning for gaucher disease by china nmpa was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA )
Also on site :
- Trump Wants To”Unleash Hell” In 2026; POTUS Tries To Go Full Maximus With A Misguided ‘Gladiator’ Flex
- GCE Global Solutions Corp. Announces Strategic Acquisition of GCE Payroll Advisers Inc. to Strengthen Global EOR and Payroll Platform
- Mickey Rourke Sued for $59,100 in Unpaid Rent, Facing Eviction